

Thomas L Frandsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1674839/publications.pdf>

Version: 2024-02-01

83
papers

3,032
citations

172386

29
h-index

175177

52
g-index

88
all docs

88
docs citations

88
times ranked

3075
citing authors

#	ARTICLE	IF	CITATIONS
1	The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin. <i>Journal of Cell Biology</i> , 2001, 152, 777-784.	2.3	307
2	Functional overlap between two classes of matrix-degrading proteases in wound healing. <i>EMBO Journal</i> , 1999, 18, 4645-4656.	3.5	225
3	Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. <i>Lancet Oncology</i> , The, 2016, 17, e231-e239.	5.1	194
4	Mercaptopurine/Methotrexate Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 503-517.	0.3	181
5	Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. <i>Breast Cancer Research and Treatment</i> , 1993, 24, 241-255.	1.1	112
6	Asparaginase-associated pancreatitis in children. <i>British Journal of Haematology</i> , 2012, 159, 18-27.	1.2	101
7	Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. <i>Lancet Oncology</i> , The, 2017, 18, 1238-1248.	5.1	87
8	Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. <i>Blood</i> , 2018, 131, 2475-2484.	0.6	83
9	1 α ,25-Dihydroxyvitamin D ₃ inhibits the invasive potential of human breast cancer cells in vitro. <i>Clinical and Experimental Metastasis</i> , 1994, 12, 195-202.	1.7	75
10	Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. <i>Oncogene</i> , 2003, 22, 4389-4397.	2.6	72
11	Complying with the European Clinical Trials directive while surviving the administrative pressure – An alternative approach to toxicity registration in a cancer trial. <i>European Journal of Cancer</i> , 2014, 50, 251-259.	1.3	72
12	Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1638-1646.	0.8	72
13	Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. <i>British Journal of Haematology</i> , 2014, 165, 126-133.	1.2	71
14	Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia – a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. <i>British Journal of Haematology</i> , 2015, 168, 547-552.	1.2	65
15	Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. <i>F1000Research</i> , 2017, 6, 444.	0.8	62
16	Hormone resistance, invasiveness, and metastatic potential in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1993, 24, 227-239.	1.1	58
17	Toxicity profile and treatment delays in “NOPHO ALL2008” comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2016, 96, 160-169.	1.1	57
18	Asparaginase-associated pancreatitis: a study on phenotype and genotype in the NOPHO ALL2008 protocol. <i>Leukemia</i> , 2017, 31, 325-332.	3.3	55

#	ARTICLE	IF	CITATIONS
19	Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. <i>Leukemia</i> , 2020, 34, 336-346.	3.3	53
20	Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age. <i>Journal of Clinical Oncology</i> , 2020, 38, 145-154.	0.8	49
21	A Precise and Efficient Stereological Method for Determining Murine Lung Metastasis Volumes. <i>American Journal of Pathology</i> , 2001, 158, 1997-2003.	1.9	44
22	Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. <i>Haematologica</i> , 2017, 102, e175-e178.	1.7	44
23	Evolution of modularity literature: a 25-year bibliometric analysis. <i>International Journal of Operations and Production Management</i> , 2017, 37, 703-747.	3.5	42
24	Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 2373-2382.	0.6	42
25	Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1935-1942.	0.8	37
26	Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27300.	0.8	36
27	Trypsin-encoding <i>PRSS1-PRSS2</i> variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. <i>Haematologica</i> , 2019, 104, 556-563.	1.7	36
28	Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota. <i>International Journal of Cancer</i> , 2020, 147, 1953-1962.	2.3	32
29	Incorporation of 6-thioguanine Nucleotides into DNA During Maintenance Therapy of Childhood Acute Lymphoblastic Leukemia—The Influence of Thiopurine Methyltransferase Genotypes. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 670-674.	1.0	31
30	Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol—Pharmacokinetics and antibody formation. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26686.	0.8	31
31	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. <i>Thrombosis and Haemostasis</i> , 2004, 91, 403-411.	1.8	28
32	Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 983-994.	1.1	28
33	Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 213-220.	1.2	27
34	Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0212157.	1.1	27
35	Clinical features and early treatment response of central nervous system involvement in childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1416-1421.	0.8	26
36	Play interventions for paediatric patients in hospital: a scoping review. <i>BMJ Open</i> , 2021, 11, e051957.	0.8	26

#	ARTICLE	IF	CITATIONS
37	Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, 32-38.	0.8	25
38	Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26909.	0.8	24
39	Bovine Colostrum Against Chemotherapy-induced Gastrointestinal Toxicity in Children With Acute Lymphoblastic Leukemia: A Randomized, Double-blind, Placebo-controlled Trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 337-347.	1.3	24
40	Everyday life challenges among adolescent and young adult survivors of childhood acute lymphoblastic leukemia: An in-depth qualitative study. <i>Psycho-Oncology</i> , 2020, 29, 1630-1637.	1.0	22
41	Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26519.	0.8	20
42	Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 59-66.	1.1	19
43	Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in <i>DDX41</i> . <i>Genes Chromosomes and Cancer</i> , 2018, 57, 670-674.	1.5	19
44	Role of TPMT and ITPA variants in mercaptopurine disposition. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 579-586.	1.1	18
45	Effects of a physical activity program from diagnosis on cardiorespiratory fitness in children with cancer: a national non-randomized controlled trial. <i>BMC Medicine</i> , 2020, 18, 175.	2.3	18
46	Testing physical function in children undergoing intense cancer treatment—a RESPECT feasibility study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27100.	0.8	17
47	Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1089-1093.	1.1	16
48	Successful Treatment of Rhino-Orbital-Cerebral Mucormycosis in a Child With Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e211-e215.	0.3	16
49	Increments in DNA-thioguanine level during thiopurine-enhanced maintenance therapy of acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2824-2833.	1.7	15
50	Effect of NCAM-transfection on growth and invasion of a human cancer cell line. <i>Apmis</i> , 1997, 105, 919-930.	0.9	14
51	Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28793.	0.8	13
52	The association between glucocorticoid therapy and BMI z-score changes in children with acute lymphoblastic leukemia. <i>Supportive Care in Cancer</i> , 2015, 23, 3573-3580.	1.0	12
53	Serial Ultrasound Monitoring for Early Recognition of Asparaginase Associated Pancreatitis in Children With Acute Lymphoblastic Leukemia. <i>Pediatric Hematology and Oncology</i> , 2015, 32, 474-481.	0.3	11
54	Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. <i>Blood Advances</i> , 2022, 6, 138-147.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 225-237.	1.1	10
56	Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study. <i>British Journal of Haematology</i> , 2011, 155, 244-247.	1.2	10
57	Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27437.	0.8	10
58	Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2020, 15, e0231209.	1.1	10
59	National, clinical cohort study of late effects among survivors of acute lymphoblastic leukaemia: the ALL-STAR study protocol. <i>BMJ Open</i> , 2021, 11, e045543.	0.8	9
60	Association between body mass index and pancreatitis in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27071.	0.8	8
61	Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials. <i>Pediatric Blood and Cancer</i> , 2016, 63, 865-871.	0.8	7
62	Early presentation of osteonecrosis in acute lymphoblastic leukemia: Two children from the Nordic and Baltic cohort. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26624.	0.8	7
63	Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial. <i>European Journal of Haematology</i> , 2018, 100, 53-60.	1.1	7
64	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2020, 10, CD013399.	1.5	6
65	Effect of Fish Oil Supplementation on Hyperlipidemia during Childhood Acute Lymphoblastic Leukemia Treatment - A Pilot Study. <i>Nutrition and Cancer</i> , 2020, 73, 1-5.	0.9	6
66	The cost of cure. <i>Lancet Haematology</i> , 2018, 5, e504-e505.	2.2	5
67	Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 911-917.	1.1	5
68	Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, e206-e209.	0.3	4
69	TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 227-238.	0.3	4
70	Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 361-369.	3.3	4
71	Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, 44, e628-e636.	0.3	4
72	Rehabilitation Including Structured Active Play for Preschoolers With Cancer (RePlay) Study Protocol for a Randomized Controlled Trial. <i>Frontiers in Pediatrics</i> , 2022, 10, .	0.9	4

#	ARTICLE	IF	CITATIONS
73	Plasminogen activator inhibitor type 1 (PAI-1), in cancer: A potential new target for antiinvasive and antimetastatic therapy. <i>Drugs of the Future</i> , 1998, 23, 873.	0.0	3
74	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. <i>The Cochrane Library</i> , 2019, , .	1.5	2
75	The Urokinase Plasminogen Activation System in Breast Cancer. , 1999, , 325-345.		1
76	Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. <i>Blood</i> , 2016, 128, 585-585.	0.6	1
77	A novel chemosensitivity profiling platform for small acute lymphoblastic leukemia cell populations. <i>Leukemia and Lymphoma</i> , 2015, 56, 2208-2211.	0.6	0
78	A Retrospective Multicenter Study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO) on Cerebral Sinus Venous Thromboses in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 584-584.	0.6	0
79	Intra-Tumoral Blast Heterogeneity and Implications for Minimal Residual Disease Detection in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 1076-1076.	0.6	0
80	Flow Cytometric Leukemic Blasts Detection in Cerebrospinal Fluid of Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3799-3799.	0.6	0
81	A Novel Chemosensitivity Profiling Platform for Small Acute Lymphoblastic Leukemia Cell Populations. <i>Blood</i> , 2014, 124, 3790-3790.	0.6	0
82	Venous Thromboembolism in Children with Acute Lymphoblastic Leukemia in Northern Europe. <i>Blood</i> , 2014, 124, 3652-3652.	0.6	0
83	<i>The Association between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol</i>. <i>Blood</i> , 2020, 136, 30-30.	0.6	0